AVTX

NASDAQ · Biotechnology

Avalo Therapeutics Inc

Small-Cap Stocks Biotech Stocks Healthcare Stocks

$18.41

-0.60 (-3.16%)

As of May 16, 2:02 AM ET ·

AVTX News1 articles

Avalo Therapeutics Soars 34% on $375M Offering Following Positive Phase 2 HS Data

Avalo Therapeutics shares surged 34% after pricing a $375M public offering, following positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company aims to fund Phase 3 development.